Massachusetts General Hospital

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Massachusetts General Hospital sits in the top decile of US sponsors by registered trial count (#4 of 15,751 sponsors by registered trial count).

2,032 total trials 336 currently recruiting 1284 completed early-phase tilt top decile by trial count

Massachusetts General Hospital: 2,032 sponsored US clinical trials, 336 recruiting.

Massachusetts General Hospital sponsors 2,032 registered US clinical trials on ClinicalTrials.gov, 336 of them currently recruiting, and 1,284 completed. 240 of these trials are in Phase 3-4 (later-stage) and 515 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Depression, with 29 trials.

Top-decile sponsor footprint

Massachusetts General Hospital ranks in the top decile of sponsors by registered trial count (#4 of 15,751 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Open and recent trials

2,032 total, page 28 of 41

TERMINATED Phase 4

Neurobiological Bases of Placebo Response in Major Depressive Disorder

NCT01787240

COMPLETED NA

Evaluation of PET/MRI in Children With Cancer

NCT01839747

COMPLETED

Implementation of CPT for PTSD in Diverse Communities

NCT01702168

COMPLETED

Effect of Propofol on Internal Anal Sphincter Pressure During ARM

NCT01793753

COMPLETED NA

Study Assessing Impact of Dermatology Consultation for Patients Admitted With Cellulitis

NCT01706913

COMPLETED

Symptom Tracking in Assisted Reproductive Technologies

NCT01746797

COMPLETED

Cross-Sectional Iloperidone IVGTT

NCT01686815

TERMINATED NA

Prevention of Delirium After Bone Marrow Transplantation

NCT01700816

COMPLETED NA

Molecular and Functional PET-fMRI Measures of Analgesia in Migraine

NCT01970943

COMPLETED NA

Implementation of ACT Through Facebook for Teenagers With Asthma

NCT01675921

COMPLETED NA

Combined Electroencephalogram, Magnetic Resonance Imaging-Positron Emission Tomography of Dexmedetomidine Induced Sleep

NCT01485380

COMPLETED Phase 1

Lenalidomide Plus Chemotherapy for AML

NCT01681537

COMPLETED

The Impact of Gratitude on Biology and Behavior in Persons With Heart Disease

NCT01709669

COMPLETED NA

Building on a Point-of-purchase Intervention to Encourage Healthy Food Choices

NCT01604499

COMPLETED NA

The Effect of Calorie Deprivation on Adipose Tissue Distribution

NCT01658397

COMPLETED

Lidocaine Serum Levels in Healthy Adult Volunteers: a Pilot Evaluation of the J-Tip Delivery System

NCT01674075

COMPLETED NA

Efficacy Study of a Novel Device to Clean the Endotracheal Tube

NCT01765530

COMPLETED Phase 4

Prevention of Stimulant-Induced Euphoria With an Opioid Receptor Antagonist

NCT01673594

TERMINATED NA

Optimal Surgical Treatment Of Fulminant Clostridium Difficile Colitis

NCT01441271

COMPLETED NA

Improving Diabetes Outcomes Through Lifestyle Change (IDOLc)Study

NCT01665989

COMPLETED Phase 4

Effectiveness Study of the Drug Tranexamic Acid to Reduce Post-surgery Blood Loss in Spinal Surgery

NCT02063035

COMPLETED NA

Educational Intervention to Reduce Outpatient Inappropriate Transthoracic Echocardiograms

NCT01944202

TERMINATED Phase 2

Simvastatin Augmentation of Lithium Treatment in Bipolar Depression

NCT01665950

COMPLETED NA

Pre-Operative Nodal Staging of Thyroid Cancer Using USPIO MRI: Preliminary Study

NCT01927887

COMPLETED

Optional Follow-up Visits for Common, Low-risk Arm Fractures

NCT01583556

COMPLETED Phase 2

Busulfan/Clofarabine + Allogeneic Stem Cell Transplantation

NCT01643668

COMPLETED NA

A Modernized Approach to Prenatal Care in Low Risk Women

NCT01606774

COMPLETED Phase 2

Normobaric Oxygen (NBO) Therapy in Acute Migraine

NCT01542307

COMPLETED NA

Effects of Eszopiclone on Sleep and Memory in Schizophrenia

NCT01641900

COMPLETED NA

Re-differentiation of Radioiodine-Refractory BRAF V600E-mutant Papillary Thyroid Carcinoma With GSK2118436

NCT01534897

COMPLETED Phase 1

Brentuximab Vedotin for Steroid Refractory GvHD

NCT01596218

TERMINATED Phase 1

Leflunomide+Vemurafenib in V600 Mutant Met. Melanoma

NCT01611675

TERMINATED Phase 4

Patient Satisfaction With Pain Relief After Ambulatory Hand Surgery

NCT01588158

COMPLETED Phase 2

Cabozantinib in Advanced Solid Malignancies

NCT01588821

COMPLETED NA

Audio-enhanced Analgesia in Healthy Subjects

NCT01835275

COMPLETED Phase 1

Understanding "Heparin Resistance" in Cardiac Surgery

NCT01598883

COMPLETED Phase 1

XL184 For Relapsed/Refractory Multiple Myeloma (MM) With Bone Disease

NCT01582295

COMPLETED

Point-of-Care Ultrasound in Greater Trochanteric Pain Syndrome

NCT01642043

COMPLETED Phase 2

Text to Move (TTM)Study

NCT01569243

COMPLETED NA

The Neurobiology of Expectancy and Pain Perception

NCT01575106

COMPLETED NA

Nasal Mask Ventilation During the Induction of General Anesthesia

NCT01651286

COMPLETED NA

Circadian Rhythms and Sleep-Wake Cycles in Parkinson's Disease

NCT01742182

COMPLETED Phase 1

Nutrition, Exercise, and Wellness Treatment (NEW Tx) for Bipolar Disorder

NCT01615367

COMPLETED NA

Imaging Study of the Lungs During an Allergic Asthma Attack

NCT01547286

COMPLETED NA

Memantine for Executive Dysfunction in Adults With ADHD: A Pilot Study

NCT01533493

COMPLETED Phase 2

Olaparib in Adults With Recurrent/Metastatic Ewing's Sarcoma

NCT01583543

COMPLETED NA

Therapy for Undergraduate College Students Who Binge Drink and Are Depressed

NCT01632319

COMPLETED Phase 2

Effects of Acipimox on Mitochondrial Function in Obesity

NCT01488409

COMPLETED NA

External-Beam Partial-Breast Irradiation for Early Breast Cancer 40 Gy QD Over 2 Weeks

NCT01581619

COMPLETED NA

The Medication Metronome Project - Study to Facilitate Follow-up Testing Resulting From Prescribed Medications to Improve Patient Safety and Care

NCT01586897

← Previous Page 28 of 41 Next →

Phase Distribution

PhaseTrial count
Phase 1 226
Phase 2 289
Phase 3 58
Phase 4 182

What is open in the Massachusetts General Hospital pipeline

336 recruiting of 2,032 indexed (17% open); 1,284 completed (63%).

Phase mix: 240 late (III/IV) vs 515 early (I/II) (early-phase heavy).

Top condition: Depression (29 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial from this sponsor, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.